- Home
- AKTX vs MRSN Comparison
AKTX vs MRSN Comparison
Compare AKTX & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- MRSN
- Stock Information
- Founded
- AKTX N/A
- MRSN 2001
- Country
- AKTX United States
- MRSN United States
- Employees
- AKTX N/A
- MRSN N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- MRSN Health Care
- Exchange
- AKTX Nasdaq
- MRSN Nasdaq
- Market Cap
- AKTX 35.7M
- MRSN 37.0M
- IPO Year
- AKTX N/A
- MRSN 2017
- Fundamental
- Price
- AKTX $1.01
- MRSN $7.16
- Analyst Decision
- AKTX Strong Buy
- MRSN Strong Buy
- Analyst Count
- AKTX 1
- MRSN 4
- Target Price
- AKTX $5.00
- MRSN $63.67
- AVG Volume (30 Days)
- AKTX 39.3K
- MRSN 137.0K
- Earning Date
- AKTX 08-13-2025
- MRSN 08-13-2025
- Dividend Yield
- AKTX N/A
- MRSN N/A
- EPS Growth
- AKTX N/A
- MRSN N/A
- EPS
- AKTX N/A
- MRSN N/A
- Revenue
- AKTX N/A
- MRSN $34,769,000.00
- Revenue This Year
- AKTX N/A
- MRSN N/A
- Revenue Next Year
- AKTX N/A
- MRSN $1.03
- P/E Ratio
- AKTX N/A
- MRSN N/A
- Revenue Growth
- AKTX N/A
- MRSN 16.14
- 52 Week Low
- AKTX $0.85
- MRSN $5.21
- 52 Week High
- AKTX $4.22
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- AKTX 43.30
- MRSN 48.25
- Support Level
- AKTX $0.94
- MRSN $5.21
- Resistance Level
- AKTX $1.13
- MRSN $7.72
- Average True Range (ATR)
- AKTX 0.06
- MRSN 0.53
- MACD
- AKTX 0.00
- MRSN 0.07
- Stochastic Oscillator
- AKTX 36.79
- MRSN 77.84
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.